Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Early onset colorectal cancer in Pakistan: Frequency and association with stage and grade.

Uzma Shamsi Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15709

e15709 Background: The disproportionate rise in early onset colorectal cancer (CRC) constitutes a critical public health issue. The objective of the study...

Incidence of concurrent pathogenic variants in <i>BRCA1</i> breast cancer patients.

Angel Lok Yiu Lee, Diana Kantarovich, Divya Rao et al. Jun 01, 2025 pp. 10586-10586 10.1200/jco.2025.43.16_suppl.10586

10586 Background: Over the years, advancements in genetic testing have led to an expansion in the number of detectable mutations. This progress has enable...

Trends and disparities in cerebrovascular disease–related mortality in older adults with colorectal cancer: A nationwide retrospective analysis.

Humza Saeed, Iqra Shahid, Sufyan Shahid et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22561

e22561 Background: Older cancer patients, particularly those with colorectal cancer (CRC), are at increased risk for incidence and complications of cerebr...

Impact of telemedicine on access to care in surgical oncology clinics: Distance and time to visit analysis for new patients at a multispecialty cancer center.

Vijaya Parameswaran, Sean Tsung, Yan Bo Zeng et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23345

e23345 Background: Telemedicine enables patients to attend visits remotely and is associated with shorter wait times (i.e. scheduling-to-appointment durat...

A comprehensive analysis of primary malignant brain tumors radiotherapy in a low-resourced country: A single-institution retrospective study.

Sergo Mkhitaryan, Samvel Bardakhchyan, Araksi Gasparyan et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14035

e14035 Background: The purpose of this study is to investigate radiation treatment of primary malignant brain tumors in a country with limited resources a...

Treatment outcomes in patients with myelofibrosis and platelets ≥50 x10 <sup>9</sup> /L treated with pacritinib in the United States.

Michael Marrone, Samantha Eiffert, Lisa Morere et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18585

e18585 Background: Pacritinib (PAC), a JAK1 sparing JAK2/IRAK1/ACVR1 inhibitor, has shown clinically significant spleen volume and symptom reduction in pa...

Association between hemoglobin levels and cancer risk: An analysis using NHANES 2017–2020 data.

Viraj Panchal, Vedant Shah, Anaiya Singh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e22588

e22588 Background: Hemoglobin (Hb) levels have been implicated in various malignancies. Anemia serves as an early indicator for leukemia, conversely, elev...

Enhancing tumor microenvironment composition to favor PD-1 inhibition via pretreatment with low-dose per fraction radiotherapy in a mouse breast cancer model.

Byoung Hyuck Kim, Jeanny Kwon Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e14556

e14556 Background: Despite recent advancements with immune checkpoint inhibitors, a significant proportion of patients, particularly those with triple-neg...

A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dai Maruyama, Erica J. Gomez, Muhammad Jalaluddin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps7093

TPS7093 Background: Chemoimmunotherapy successfully treats ~60% of patients (pts) with diffuse large B-cell lymphoma (DLBCL), the most common form of B-ce...

Impact of vascular microenvironment on prognosis in hepatocellular carcinoma: A quantitative feature analysis.

Hong Yu, Zhiqiang Cheng, Xiang Xia Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16293

e16293 Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally. The vascular component of the tumor microenviro...

Phase 3 study of benmelstobart in combination with chemotherapy followed by sequential combination with anlotinib for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC).

Yuankai Shi, Longhua Sun, Runxiang Yang et al. Jun 01, 2025 pp. 8514-8514 10.1200/jco.2025.43.16_suppl.8514

8514 Background: PD-1/ PD-L1 inhibitors plus platinum-based chemotherapy is the standard first-line therapy for locally advanced or metastatic sq-NSCLC. I...

Observational study of prevalence, management, and outcomes of synchronous oligometastatic non-small cell lung cancer.

Anokhi Shah, Sree Siva Kumar Raja Addagalla, Nandini Sharrel Menon et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20516

e20516 Background: Oligometastatic non-small cell lung cancer (NSCLC), characterized by one to five metastatic lesions in up to three organs, represents a...

Exploring racial disparities in biliary tract cancer with sepsis.

Barath Prashanth Sivasubramanian, Diviya Bharathi Ravikumar, Anushka Dhabuwala et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16185

e16185 Background: Biliary tract cancers (BTCs) account for 3% of all cancers. In 2021, the incidence of BTCs was 15.8 per 100,000 among Hispanics (HP), 1...

The association of ctDNA with recurrence in patients with stage II-IV colorectal cancer: The β-CORRECT study.

Tadayoshi Hashimoto, Yoshiaki Nakamura, Gregory Young et al. Jun 01, 2025 pp. 3590-3590 10.1200/jco.2025.43.16_suppl.3590

3590 Background: CRC is a leading cause of cancer-related mortality globally. Detection of molecular residual disease (MRD) is an early indicator of recur...

Outcomes of split-dose lymphocyte-adjusted rabbit ATG in allogeneic stem cell transplant recipients.

Michael Williams, Brittany Mejaki, Erin Franzen et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18560

e18560 Background: Despite advances in graft versus host disease (GVHD) prevention, rabbit antithymocyte globulin (rATG) remains a guideline-based option...

Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

Shilpa Gupta, Jens Bedke, Michiel Simon Van Der Heijden et al. Jun 01, 2025 pp. 4502-4502 10.1200/jco.2025.43.16_suppl.4502

4502 Background: EV-302/KEYNOTE-A39 (NCT04223856) showed significant PFS and OS benefits for pts with previously untreated la/mUC treated with EV+P vs che...

Impact of immune checkpoint inhibitor (ICI)-associated autoimmune hemolytic anemia (AIHA) on mortality in cancer patients: A retrospective analysis.

Haris Sohail, Nisar Amin, Jennifer Collins et al. Jun 01, 2025 pp. 2649-2649 10.1200/jco.2025.43.16_suppl.2649

2649 Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can cause serious immune-related adverse events; including r...

Prognostic and predictive role of HLA supertypes in pMMR mCRC patients receiving FOLFOXIRI/bev ± atezolizumab in the AtezoTRIBE study.

Daniele Rossini, Roberto Moretto, Francesca Battaglin et al. Jun 01, 2025 pp. 3547-3547 10.1200/jco.2025.43.16_suppl.3547

3547 Background: The HLA system plays a crucial role in the development of the adaptive immune response, influencing antigen presentation and T-cell-media...

Digital profiling of tumor-derived extracellular vesicle-RNA: A sensitive approach for early detection of EGFR mutations in osimertinib-resistant non-small cell lung cancer.

Beomseok Lee, Jihye Ahn, Jueun Kwon et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20076

e20076 Background: Osimertinib resistance in EGFR-mutant non-small cell lung cancer (NSCLC) patients presents a significant challenge due to limited post-...

United States treatment pattern response to carboplatin and cisplatin shortages.

John Kent Lin, Ying Xu, Mariana Chavez Mac Gregor et al. Jun 01, 2025 pp. 11088-11088 10.1200/jco.2025.43.16_suppl.11088

11088 Background: In response to cisplatin (2/10/23) and carboplatin (4/28/23) shortages, national guidelines recommended prioritizing cisplatin and carbo...

Machine learning–driven approaches for predicting T-cell–mediated immunity and beyond.

Chongming Jiang, Yulun Chiu, Cassian Yee et al. Jun 01, 2025 pp. 2588-2588 10.1200/jco.2025.43.16_suppl.2588

2588 Background: Recognition of peptides presented by the major histocompatibility complex (MHC) through the T cell receptor (TCR-pMHC) is crucial for T c...

Effect of chemotherapy drug cisplatin on the efficacy of B7H3 CAR-T cells in treating melanoma by increasing target antigen density.

Yongwei Zheng, Guangchao Li, Zhixiang Li et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21562

e21562 Background: B7H3 is overexpressed in multiple types of solid tumors, including melanoma, making it an ideal target for chimeric antigen receptor (C...

Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results.

Haiping Jiang, Mingzhu Huang, Lixin Wan et al. Jun 01, 2025 pp. 4039-4039 10.1200/jco.2025.43.16_suppl.4039

4039 Background: Claudin 18.2 (CLDN18.2), a tight junction protein highly expressed in gastric and gastroesophageal junction (GEJ) cancers, has emerged as...

Mayhem under the microscope: T cell cytotoxicity and serial killers captured in situ.

Greg Sawyer, Patrick Hwu, Fredrick Locke et al. Jun 01, 2025 pp. 2540-2540 10.1200/jco.2025.43.16_suppl.2540

2540 Background: Developing a deeper understanding of the dynamics of immune cell-mediated cytotoxicity is critical to advancing immunotherapy and cell th...

Concurrent chemoradiotherapy in locally advanced lung cancer with cisplatin-etoposide or carboplatin-paclitaxel: An institutional analysis.

Dipanjan Debnath, Abigail Arrigo, Madhurima Debnath et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e20042

e20042 Background: In patients with unresectable locally advanced non-small cell lung cancer (NSCLC), chemotherapy given concurrently with radiation (CRT)...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page